Cyxone – Building stronger, safer bridges to health
Treatments for diseases such as rheumatoid arthritis, multiple sclerosis and virally induced acute respiratory disorders such as Covid 19 have come a long way but still have several shortcomings. These include adverse side effects, administration forms that often require visits to the hospital, and poor response or resistance in some patients. Cyxone is a clinical-stage biotech company focusing on the development of treatments that are administered early stage, have fewer, less severe side effects, can be taken on an outpatient basis and are showing promising response in early clinical trials. To put it simply, Cyxone’s treatments will increase the quality of life for millions of people.